Physician profile
Poonam Batchu
NPI 1689273930
$750.54
in general payments reported to CMS, 2019-2025
12 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.60 · 2024: $398 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $167.96 | 2024-2025 | Jynarque |
| Astrazeneca Pharmaceuticals Lp | $117.68 | 2024-2025 | Farxiga |
| Amgen INC. | $104.91 | 2022-2025 | Tavneos, Parsabiv, Aranesp |
| Ardelyx, INC. | $88.24 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $68.30 | 2024 | Velphoro |
| Ani Pharmaceuticals, INC. | $51.98 | 2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $45.66 | 2024 | |
| Glaxosmithkline, LLC. | $33.33 | 2024-2025 | Benlysta |
| Apellis Pharmaceuticals, INC. | $24.41 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $21.09 | 2025 | |
| Vifor Pharma, INC. | $13.80 | 2024 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.18 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poonam Batchu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.